- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Teduglutide – November 2017
Teduglutide: Powder for injection 5 mg with solvent; Revestive®
Last updated
16 March 2018